GLP-1 Market
LLY $1169.60 ▼ -1.6% NVO $38.18 ▼ -0.2% PFE $27.82 ▼ -0.6% VKTX $27.73 ▼ -2.8% KLRA $10.00 ▼ -5.0% GPCR $25.67 ▼ -3.8% RHHBY $53.29 ▼ -1.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

DCR-PHXC

Company
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 9, 2026

Find a Clinical Trial Near Me

See recruiting studies for DCR-PHXC and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04580420

    Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

    Not yet reported Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 28 participants Est. completion 2032-01-30 18 sites Stand-alone
    Other conditions: Primary Hyperoxaluria Type 1, End Stage Renal Disease
    View official trial listing →
  • Completed NCT NCT03392896

    Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

    Not yet reported Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 43 participants Est. completion 2019-11-19 7 sites Stand-alone
    Other conditions: Primary Hyperoxaluria
    View official trial listing →
  • Completed NCT NCT03847909

    A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

    Not yet reported Novo Nordisk A/S 35 participants Est. completion 2021-06-29 28 sites Stand-alone
    Other conditions: Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease
    View official trial listing →
  • Active, not recruiting NCT NCT04042402

    Long Term Extension Study in Patients With Primary Hyperoxaluria

    Not yet reported Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 75 participants Est. completion 2030-04-01 23 sites Stand-alone
    Other conditions: Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3)
    View official trial listing →
  • Completed NCT NCT04555486

    Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

    Not yet reported Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 6 participants Est. completion 2021-09-07 6 sites Stand-alone
    Other conditions: Primary Hyperoxaluria Type 3
    View official trial listing →
  • Completed NCT NCT05001269

    Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

    Not yet reported Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 27 participants Est. completion 2025-02-05 13 sites Stand-alone
    Other conditions: Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
    View official trial listing →
  • No Longer Available NCT NCT05993416

    Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

    Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
    Other conditions: Primary Hyperoxaluria Type 1 (PH1)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: DCR-PHXC, Nedosiran

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.